Zhao LQ, Gao W, Zhang P, Zhang YL, Fang CY, Shou HF. Surgery in platinum-resistant recurrent epithelial ovarian carcinoma. World J Clin Cases 2022; 10(12): 3739-3753 [PMID: 35647161 DOI: 10.12998/wjcc.v10.i12.3739]
Corresponding Author of This Article
Hua-Feng Shou, MD, Department of Gynecology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. shouhuafeng@hmc.edu.cn
Research Domain of This Article
Surgery
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ling-Qin Zhao, Wen Gao, Ping Zhang, Ying-Li Zhang, Chen-Yan Fang, Department of Gynecologic Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, Zhejiang Province, China
Hua-Feng Shou, Department of Gynecology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Author contributions: Zhao LQ and Gao W contributed to conceptualization, data curation, and writing - review & editing; CY Fang, Zhang P contributed to formal analysis and methodology; Zhao LQ, Gao W, YL Zhang, and Shou HF contributed to writing - original draft; Zhao LQ and Gao W contributed equally to this work; all authors read and approved the final manuscript.
Supported bythe Medical Science Project of Zhejiang Province, No. 2018KY027.
Institutional review board statement: The research adhered to the principles of the Declaration of Helsinki and Title 45, United States. Code of Federal Regulations, Part 46, Protection of Human Subjects. The present study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital. The study has obtained informed consent for all individual participants that appear in this manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors of this work have nothing to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at shouhuafeng@hmc.edu.cn.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—a checklist of items.
Corresponding author: Hua-Feng Shou, MD, Department of Gynecology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Xiacheng District, Hangzhou 310014, Zhejiang Province, China. shouhuafeng@hmc.edu.cn
Received: October 1, 2021 Peer-review started: October 1, 2021 First decision: December 10, 2021 Revised: December 24, 2021 Accepted: March 6, 2022 Article in press: March 6, 2022 Published online: April 26, 2022 Processing time: 201 Days and 22 Hours
ARTICLE HIGHLIGHTS
Research background
Ovarian cancer is one of the three most common malignant tumors of the female reproductive tract and ranks first in terms of mortality among gynecological tumors. Epithelial ovarian carcinoma (EOC) is the most common ovarian malignancy, accounting for 90% of all primary ovarian tumors.
Research motivation
The clinical value of cytoreductive surgery in patients with platinum-resistant recurrent EOC remains largely unclear.
Research objectives
This study aimed to evaluate the feasibility of secondary cytoreductive surgery to treat platinum-resistant recurrent EOC.
Research methods
It was a retrospective study of the clinical data of patients with platinum-resistant EOC admitted to the Cancer Hospital of the University of Chinese Academy of Sciences between September 2012 and June 2018.
Research results
R0 resection and postoperative chemotherapy significantly prolonged progression-free survival and overall survival (all P < 0.05), and R0 resection also significantly prolonged chemotherapy-free interval (P < 0.05).
Research conclusions
Secondary cytoreductive surgery is feasible for the treatment of platinum-resistant recurrent EOC.
Research perspectives
The findings provide important references for the selection of clinical therapeutic regimens.
